Press Journals

Acne Vulgaris Therapeutics Pipeline Has Moved Towards the Development of Biologicals and Peptides

November 2017

Acne vulgaris currently exhibits a growing pipeline with approximately 49 drug candidates. According to P&S Market Research

Positive Clinical Results Supporting the Pipeline Growth

Various drug candidates have shown positive clinical results and are proceeding towards further development. For instance, In May 2017, Foamix Ltd. announced that FMX101 was generally safe and well tolerated with no drug-related serious adverse events from two double-blind, randomized, placebo-controlled Phase III trials for the treatment of moderate-to-severe acne vulgaris. AndroScience Corporation announced that ASC-J9 in a cream formulation demonstrated a therapeutic effect in lowering lesion counts in moderate to severe acne.

Acne Vulgaris Therapeutics Pipeline has moved towards the development of biologicals and peptides

Access Report Summary with Detailed TOC on "Acne Vulgaris Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments" at: https://www.psmarketresearch.com/market-analysis/acne-vulgaris-therapeutics-pipeline-analysis

According to the research findings, the drug candidates in acne vulgaris pipeline have move from small molecule towards biologics and peptides. Allergan plc is in the process of manufacturing ANT-1207, also known as botulinum toxin A topical, under the Phase II stage of development for the treatment of acne vulgaris. The therapeutic candidate is an anticholinergic agent, being developed to be administered by topical route. Helix Biomedix, Inc. in a process of developing peptide based molecule, which is in the unknown stage for the treatment of acne vulgaris.

Various Technologies for Targeted Drug Delivery Driving the Growth of the Pipeline

Most of the companies possess advanced technologies for the development of acne vulgaris. For instance, Sol-Gel Technologies Ltd. introduced a technology known as “sol-gel”, in which silica on site forms a microcapsule shells and release drugs at site of action. The drug substance that is added during the sol-gel reaction is encapsulated, through which a core-shell structure is formed. Therefore, the contribution of advanced technologies for making targeted therapies is a key factor driving the growth of acne vulgaris pipeline therapeutics.

Some of the key players developing drugs for the treatment of acne vulgaris therapeutics pipeline include Sol-Gel Technologies Ltd., Realm Therapeutics, Inc., Sienna Biopharmaceuticals, Inc., and Promius Pharma, LLC (subsidiary of Dr. Reddy’s Laboratories Ltd.).

Acne Vulgaris Therapeutics Pipeline Analysis

  • By Phase
  • By Molecule Type
  • By Route of Administration
  • By Company